LacCer(d18:1/22:0) (BioDeep_00000032131)
human metabolite Endogenous
代谢物信息卡片
化学式: C52H99NO13 (945.7116043999999)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(feces) 95.24%
分子结构信息
SMILES: CCCCCCCCCCCCCCCCCCCCCC(=O)NC(COC1C(C(C(C(O1)CO)OC2C(C(C(C(O2)CO)O)O)O)O)O)C(C=CCCCCCCCCCCCCC)O
InChI: InChI=1S/C52H99NO13/c1-3-5-7-9-11-13-15-17-18-19-20-21-22-24-26-28-30-32-34-36-44(57)53-40(41(56)35-33-31-29-27-25-23-16-14-12-10-8-6-4-2)39-63-51-49(62)47(60)50(43(38-55)65-51)66-52-48(61)46(59)45(58)42(37-54)64-52/h33,35,40-43,45-52,54-56,58-62H,3-32,34,36-39H2,1-2H3,(H,53,57)/b35-33+/t40-,41+,42+,43+,45-,46-,47+,48+,49+,50+,51+,52-/m0/s1
描述信息
LacCer(d18:1/22:0) is a lactosylceramide or LacCer. Lactosylceramides are the most important and abundant of the diosylceramides. Lactosylceramides (LacCer) were originally called cytolipin H. It is found in small amounts only in most animal tissues, but it has a number of significant biological functions and it is of great importance as the biosynthetic precursor of most of the neutral oligoglycosylceramides, sulfatides and gangliosides. In animal tissues, biosynthesis of lactosylceramide involves addition of the second monosaccharides unit (galactose) as its nucleotide derivative to monoglucosylceramide, catalysed by a specific beta-1,4-galactosyltransferase on the lumenal side of the Golgi apparatus. The glucosylceramide precursor must first cross from the cytosolic side of the membrane, possibly via the action of a flippase. The lactosylceramide produced can be further glycosylated or transferred to the plasma membrane. Lactosylceramide may assist in stabilizing the plasma membrane and activating receptor molecules in the special micro-domains or rafts, as with the cerebrosides. It may also have its own specialized function in the immunological system in that it is known to bind to specific bacteria. In addition, it is believed that a number of pro-inflammatory factors activate lactosylceramide synthase to generate lactosylceramide, which in turn activates "oxygen-sensitive" signalling pathways that affect such cellular processes as proliferation, adhesion, migration and angiogenesis. Dysfunctions in these pathways can affect several diseases of the cardiovascular system, cancer and inflammatory states, so lactosylceramide metabolism is a potential target for new therapeutic treatments. beta-D-Galactosyl-1,4-beta-D-glucosylceramide is the second to last step in the synthesis of N-Acylsphingosine and is converted. from Glucosylceramide via the enzyme beta-1,4-galactosyltransferase 6(EC:2.4.1.-). It can be converted to Glucosylceramide via the enzyme beta-galactosidase (EC:3.2.1.23).
Lactosylceramide (d18:1/22:0) is a lactosylceramide or LacCer. Lactosylceramides are the most important and abundant of the diosylceramides. Lactosylceramides (LacCer) were originally called cytolipin H. It is found in small amounts only in most animal tissues, but it has a number of significant biological functions and it is of great importance as the biosynthetic precursor of most of the neutral oligoglycosylceramides, sulfatides and gangliosides. In animal tissues, biosynthesis of lactosylceramide involves addition of the second monosaccharides unit (galactose) as its nucleotide derivative to monoglucosylceramide, catalysed by a specific beta-1,4-galactosyltransferase on the lumenal side of the Golgi apparatus. The glucosylceramide precursor must first cross from the cytosolic side of the membrane, possibly via the action of a flippase. The lactosylceramide produced can be further glycosylated or transferred to the plasma membrane. Lactosylceramide may assist in stabilizing the plasma membrane and activating receptor molecules in the special micro-domains or rafts, as with the cerebrosides. It may also have its own specialized function in the immunological system in that it is known to bind to specific bacteria. In addition, it is believed that a number of pro-inflammatory factors activate lactosylceramide synthase to generate lactosylceramide, which in turn activates "oxygen-sensitive" signalling pathways that affect such cellular processes as proliferation, adhesion, migration and angiogenesis. Dysfunctions in these pathways can affect several diseases of the cardiovascular system, cancer and inflammatory states, so lactosylceramide metabolism is a potential target for new therapeutic treatments. beta-D-Galactosyl-1,4-beta-D-glucosylceramide is the second to last step in the synthesis of N-Acylsphingosine and is converted
同义名列表
37 个代谢物同义名
N-[(2S,3R,4E)-1-{[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-3-hydroxyoctadec-4-en-2-yl]docosanamide; N-[(2S,3R,4E)-1-{[4-O-(beta-D-galactopyranosyl)-beta-D-glucopyranosyl]oxy}-3-hydroxyoctadec-4-en-2-yl]docosanamide; N-[(2S,3R,4E)-1-{[4-O-(b-D-galactopyranosyl)-b-D-glucopyranosyl]oxy}-3-hydroxyoctadec-4-en-2-yl]docosanamide; N-[(2S,3R,4E)-1-{[4-O-(β-D-galactopyranosyl)-β-D-glucopyranosyl]oxy}-3-hydroxyoctadec-4-en-2-yl]docosanamide; beta-D-Galactosyl-(1->4)-beta-D-glucosyl-N-(docosanoyl)sphingosine; b-D-Galactosyl-(1->4)-b-D-glucosyl-N-(docosanoyl)sphingosine; β-D-Galactosyl-(1->4)-β-D-glucosyl-N-(docosanoyl)sphingosine; N-(Docosanoyl)-1-beta-lactosyl-D-erythro-sphingosine; N-(Docosanoyl)-1-beta-lactosyl-erythro-4-sphingenine; N-(Docosanoyl)-1-β-lactosyl-D-erythro-sphingosine; N-(Docosanoyl)-1-β-lactosyl-erythro-4-sphingenine; N-(docosanoyl)-1-beta-lactosyl-sphing-4-enine; N-(Docosanoyl)-1-beta-lactosyl-4-sphingenine; N-(Docosanoyl)-1-beta-lactosyl-D-sphingosine; N-(Docosanoyl)-1-beta-lactosyl-sphingosine; N-(Docosanoyl)-1-β-lactosyl-sphing-4-enine; N-(Docosanoyl)-1-beta-lactosyl-sphingenine; N-(Docosanoyl)-1-β-lactosyl-D-sphingosine; N-(Docosanoyl)-1-β-lactosyl-4-sphingenine; N-(Docosanoyl)-1-β-lactosyl-sphingosine; beta-Lactosyl-N-(docosanoyl)sphingosine; N-(Docosanoyl)-1-β-lactosyl-sphingenine; b-Lactosyl-N-(docosanoyl)sphingosine; β-Lactosyl-N-(docosanoyl)sphingosine; Lactosylceramide (d18:1,C22:0); Lactosylceramide (d18:1/22:0); Lactosylceramide(d18:1/22:0); beta-Lactosylceramide; LacCer(d18:1/22:0); b-Lactosylceramide; β-Lactosylceramide; LacCer d18:1/22:0; Lactosylceramide; beta-LacCer; b-LacCer; β-LacCer; CDH
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:84762
- ChEBI: CHEBI:62109
- PubChem: 52921641
- HMDB: HMDB0011594
- foodb: FDB028307
- CAS: 111142-68-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:
- PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。